Medtronic today announced expansion of the limited site release of its recently acquired radial artery access portfolio from privately-held Rist Neurovascular, following first-in-patient procedure. This portfolio includes the Rist 079 radial access guide catheter and Rist radial access selective catheter.
“Rist 079 radial access guide catheter is the first catheter that has been specifically designed for neurointerventions using the radial artery pathway in the wrist. This is the first-of-its-kind device that optimises transition zones for the required navigability and support that is unique to the radial trajectory when compared to the femoral approach,” said R Webster Crowley, chief of Cerebrovascular and Endovascular Neurosurgery, Rush University Medical Center, Chicago, USA, who performed the first-in-patient procedure in September 2020. “The Rist radial access portfolio gives clinicians who perform neurovascular procedures the full spectrum of access and delivery devices that are optimised for the patient’s condition and anatomy. This should help improve the care we deliver to patients treated for neurovascular conditions.”
According to a company press release, the addition of the Rist 079 radial access guide catheter and selective catheter to the Medtronic neurovascular portfolio enhances the company’s ability to serve patients that require interventional neurovascular therapy.
The Rist 079 radial access guide catheter and Rist radial access selective catheter received US Food and Drug Administration (FDA) 501(k) clearance last year.
According to the company, since 2018, the American Heart Association has recommended transradial techniques for cardiovascular endovascular interventions for acute coronary syndrome citing lower bleeding and vascular complications than transfemoral artery access and the neuro-interventionalist community is examining adoption of the transradial approach to their practice.